Icons8 Launches New AI-Powered Tools to Enhance Icon Design Workflow for Developers and Designers
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/11704/259660_43451cf6f4652a77_001.jpg ]
New AI features make icon work easier.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11704/259660_43451cf6f4652a77_001full.jpg
The update includes enhancements to Icons8's flagship features such as the Smart Upscaler, Background Remover, and a redesigned Image-Based Icon Search. These tools are now powered by upgraded AI models, offering faster performance, improved accuracy, and broader file support across desktop and mobile workflows.
'Streamlining icon and asset selection remains a core challenge in design workflows,' said Ivan Braun, Founder of Icons8. 'These updates help solve that problem at scale, reducing time spent on manual adjustments and supporting more unified design systems.'
A Cohesive Asset Ecosystem
In addition to the AI updates, Icons8 now offers access to over 1.42 million graphic assets organized into more than 45 visually consistent icon families. Each family maintains unified stroke weights, proportions, and stylistic elements, helping teams avoid the mismatched visuals common in many digital products.
The company also reported growth in enterprise usage and educational partnerships, driven by its REST API and Figma plugin integrations, which allow seamless access to assets within development and design environments.
Scalable Solutions for Teams of All Sizes
The upgraded platform supports a wide range of users, including:
Icons8's new features are now live and available globally via its web platform and supported design plugins.
About Icons8
Icons8 is a design asset platform offering millions of icons, illustrations, photos, and music tracks. With plugin integrations, APIs, and AI-driven tools, Icons8 helps teams streamline design workflows, maintain consistency, and build visually cohesive digital products. For more information, visit https://icons8.com.
Media Contact
Company Name: Icons8
Contact Person: Ivan Braun
Email: [email protected]
Address: 4023 Kennett Pike #59970
Country: United States
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259660
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Newton Golf Company Reports Second Quarter 2025 Financial Results
Revenue Climbs 154% Year-over-Year as Tour Adoption and Product Momentum Accelerate CAMARILLO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- via IBN – Newton Golf Company (NASDAQ: NWTG) ('Newton Golf' or the 'Company'), a technology-forward golf company delivering physics-based performance innovations, today announced financial results for the second quarter ended June 30, 2025. Second Quarter and Year-to-Date 2025 Highlights Q2 2025: Revenue increased 154% year-over-year to $2.1 million, compared to $813,000 in Q2 2024 First Six Months 2025: Revenue increased 182% year-over-year to $3.3 million, compared to $1.2 million in the first half of 2024 Q2 2025: Gross profit rose 186% to $1.4 million, up from $489,000 in Q2 2024 First Six Months 2025: Gross profit increased 224% to $2.3 million, up from $695,000 in the first half of 2024 Q2 2025: Gross margin improved to 67.6%, compared to 60.1% in Q2 2024 First Six Months 2025: Gross margin expanded to 68.7%, compared to 59.8% in the first half of 2024 Q2 2025: Net loss of $1.5 million, or ($0.34) per share, compared to a net loss of $1.2 million, or ($0.79) per share, in Q2 2024 First Six Months 2025: Net loss of $2.1 million, or ($0.74) per share, compared to a net loss of $2.4 million, or ($1.61) per share, in the first half of 2024 Cash & Equivalents: $4.0 million as of June 30, 2025 Management Commentary Greg Campbell, CEO: "Our Q2 results highlight continued progress across multiple channels, with strong performance from our Motion and Fast Motion shafts, growing adoption among tour professionals, and expanding relationships with global distributors. We also increased our marketing and sales investments this quarter to build on that momentum heading into the second half of the year." Jeff Clayborne, CFO: "It's an exciting time to join Newton Golf as we build both financial momentum and market presence. In Q2, we delivered meaningful top-line growth and maintained solid margins, supported by strong product demand and operational efficiency. We remain focused on disciplined execution as we scale, and confident in our ability to drive long-term value for shareholders." Recent Business Highlights Miguel Ángel Jiménez earned his second PGA TOUR Champions victory using the Newton Fast Motion shaft Launched on April 29, 2025, the Newton Fast Motion golf shaft has surged to become a breakout success in just its first months on the market. In May and June alone, 1,817 units generated over $696,000 in gross sales, and momentum only accelerated into Q3 with 2,211 units sold to date, producing more than $786,000 in revenue. This rapid adoption—outpacing even the established Motion line—underscores the Fast Motion's powerful market appeal, exceptional performance, and the strong demand from golfers seeking the next leap in shaft innovation. Newton's newest release is not just gaining traction—it's redefining the speed at which a premium golf shaft can capture market share. Newton surpassed 50 professional users across PGA TOUR Champions, LPGA, and Korn Ferry Tours Increased production capacity to meet accelerating demand for Motion and Fast Motion shafts Experienced significant growth in direct-to-consumer sales through Expanded distribution and product testing with international fitters and retailers, including new partnerships in Japan Newton shaft technology was highlighted by Golf Magazine's Kris McCormack as one of the most exciting new shaft innovations on the market 2025 Revenue Guidance The Company is raising its full-year 2025 revenue guidance to a range of $7.0 million to $7.5 million, up from the prior range of $6.5 million to $7.0 million issued last quarter, reflecting stronger-than-anticipated demand and continued momentum across key channels. Looking Ahead 'As we move into the second half of 2025, our focus is on scaling operations and deepening product adoption,' added Campbell. 'With new products on the horizon and expanded retail partnerships underway, we remain committed to building a differentiated, performance-driven brand.' Consolidated Results of Operations (Amounts rounded to nearest thousands, except share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net Sales $ 2,068,000 $ 813,000 $ 3,278,000 $ 1,163,000 Cost of goods sold 669,000 324,000 1,027,000 468,000 Gross profit 1,399,000 489,000 2,251,000 695,000 Operating expenses Selling, general and administrative expenses 2,763,000 1,484,000 5,304,000 2,755,000 Research and development 143,000 207,000 425,000 397,000 Total operating expenses 2,906,000 1,691,000 5,729,000 3,152,000 Loss from operations (1,507,000 ) (1,202,000 ) (3,478,000 ) (2,457,000 ) Interest income, net 29,000 47,000 74,000 109,000 Change in fair value of warrant liabilities (42,000 ) - 1,359,000 - Net loss $ (1,520,000 ) $ (1,155,000 ) $ (2,045,000 ) $ (2,348,000 ) Loss per share – basic and diluted $ (0.34 ) $ (0.79 ) $ (0.74 ) $ (1.61 ) Weighted average number of shares outstanding – basic and diluted 4,509,619 1,459,587 2,778,595 1,459,587 For more information, visit the Company's investor relations website at or contact Investor Relations at ir@ Investor Alerts Stay updated with the latest from Newton Golf! Sign up for investor alerts at to receive company news and strategic developments directly to your inbox. About NEWTON GOLF At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf equipment—including Newton Motion shafts and Gravity putters—that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced tools that maximize consistency and accuracy, ensuring every swing is backed by the laws of physics. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the future financial performance of Newton Golf Company (the 'Company') and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "expects," "plans," "anticipates," "intends," "believes," "estimates," "projects," "potential," "continues," or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the reverse stock split, the Company's ability to maintain compliance with Nasdaq listing requirements, the potential for increased institutional investor interest, the Company's future growth strategy, expansion of its product portfolio, anticipated financial performance, and future business prospects. These forward-looking statements reflect the Company's current expectations and projections based on information available as of the date of this release and are subject to a number of risks and uncertainties, including, but not limited to, general economic, financial, and business conditions; changes in consumer demand and industry trends; the Company's ability to successfully implement its strategic initiatives; competition in the golf equipment market; supply chain disruptions; regulatory compliance and legal proceedings; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company cautions investors that forward-looking statements are not guarantees of future performance and actual results may differ materially from those projected. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Media Contact: Beth GastBG Public Investor Contact: Scott McGowanInvestor Brand Network (IBN)Phone: 310.299.1717ir@ in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Leap Therapeutics Reports Second Quarter 2025 Financial Results
CAMBRIDGE, Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap Highlights: Board of Directors initiated process of exploring strategic alternatives to maximize shareholder value Strategic restructuring to prioritize corporate development resulting in a further 75% reduction in workforce Reported updated data from the randomized, controlled Part B of the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy in second-line colorectal cancer (CRC) "This past quarter, we undertook a strategic realignment to focus our resources on corporate development opportunities for sirexatamab and FL-501," said Douglas E. Onsi, President and CEO of Leap Therapeutics. "As part of this effort, we completed patient treatment in the DeFianCe trial, further reduced internal expenses, and initiated a review of strategic alternatives to maximize value for our shareholders. We intend to provide a further update in the coming weeks. We are grateful to all of our team members, and we thank them for their important contributions to Leap and their commitment to developing new therapies for cancer patients." DKN-01 Development Update Reported updated clinical data from Part B of the DeFianCe study of sirexatamab plus bevacizumab and chemotherapy in CRC patients. In the updated analysis as of May 22, 2025, sirexatamab demonstrated a statistically significant benefit on overall response rate (ORR), by investigator assessment and blinded independent central review, and progression-free survival (PFS) in patients with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis, along with a positive trend on ORR and PFS in the full intent-to-treat population. The final data from the study is being prepared for presentation at a future medical conference. Business Updates Exploring strategic alternatives to preserve and maximize shareholder value. The Board of Directors initiated a process to explore strategic alternatives to preserve and maximize shareholder value, including leveraging its cash balance and exploring potential sale or partnership opportunities for sirexatamab and FL-501. The Company's Board of Directors has approved the engagement of Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist in the strategic evaluation process. Taking additional steps to reduce spending and preserve capital. The Company implemented an additional workforce reduction of approximately 75%. The total costs related to this reduction in force, including severance payments, are estimated to be approximately $4.5 million. The majority of these costs will be recognized in the third and fourth quarters of 2025. Selected Second Quarter 2025 Financial Results Net Loss was $16.6 million for the second quarter 2025, compared to $20.4 million for the second quarter 2024. The decrease was primarily due to a decrease in research and development and general and administrative expenses, offset in part by a restructuring charge associated with the reduction in force. Research and development expenses were $10.5 million for the second quarter of 2025, compared to $17.9 million for the same period in 2024. The decrease of $7.4 million was primarily due to decreases of $3.9 million in clinical trial costs, $1.7 million in payroll and other headcount related expenses, $1.4 million in manufacturing costs, and $0.4 million in stock-based compensation expense. General and administrative expenses were $1.8 million for the second quarter 2025, compared to $3.4 million for the same period in 2024. The decrease of $1.6 million was primarily due to decreases of $1.4 million in payroll and other incentive based compensation expense and a $0.2 million decrease in stock-based compensation expense. During the second quarter of 2025, we incurred $4.5 million of restructuring charges associated with our workforce reduction, consisting primarily of one-time employee severance and benefit costs. Cash and cash equivalents totaled $18.1 million on June 30, 2025. About Leap TherapeuticsLeap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's pipeline includes sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, and FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein. For more information about Leap Therapeutics, visit or view our public filings with the SEC that are available via EDGAR at or via FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates, including sirexatamab and FL-501; Leap's plan to reduce clinical and operational activities, reduce spending and conserve cash, explore strategic alternatives to preserve and maximize shareholder value, including by leveraging its cash balance and potentially selling or partnering sirexatamab or FL-501; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully sell or enter into partnerships for sirexatamab or FL-501; (ii) the cost and timeline to complete the DeFianCe Study and wind-down operations; (iii) any regulatory feedback that Leap may receive from U.S. Food and Drug Administration (FDA) or equivalent foreign regulatory agency or from site institutional review boards; and (iv) the availability of strategic alternatives that would preserve or generate any shareholder value. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Leap may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Leap's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither Leap, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Leap's views as of any date subsequent to the date hereof. CONTACT: Douglas E. OnsiPresident & Chief Executive OfficerLeap Therapeutics, Inc.617-714-0360donsi@ Matthew DeYoungInvestor RelationsArgot Partners212-600-1902leap@ Leap Therapeutics, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited)Three Months Ended June 30, Six Months Ended June 30, 2025202420252024 Operating expenses: Research and development$ 10,537$ 17,885$ 23,448$ 29,184 General and administrative 1,817 3,367 4,823 6,893 Restructuring charges 4,527 — 4,527 — Total operating expenses 16,881 21,252 32,798 36,077 Loss from operations (16,881) (21,252) (32,798) (36,077) Interest income 246 865 683 1,640 Interest expense (7) — (13) — Australian research and development incentives 1 253 56 499 Foreign currency gain (loss) (2) 6 (6) (10) Net loss$ (16,643)$ (20,128)$ (32,078)$ (33,948) Dividend attributable to down round feature of warrants — (234) — (234) Net loss attributable to common stockholders$ (16,643)$ (20,362)$ (32,078)$ (34,182)Net loss per share Basic and diluted$ (0.40)$ (0.52)$ (0.78)$ (1.01)Weighted average common shares outstanding Basic and diluted 41,444,979 39,122,662 41,357,423 33,830,083 Leap Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts)June 30, December 31, 20252024 Assets Current assets: Cash and cash equivalents$ 18,130$ 47,249 Research and development incentive receivable 739 704 Prepaid expenses and other current assets 292 86 Total current assets 19,161 48,039Right of use assets, net 38 262 Research and development incentive receivable, net of current portion 59 — Deposits 784 823 Total assets$ 20,042$ 49,124Liabilities and Stockholders' Equity Current liabilities: Accounts payable$ 7,339$ 4,743 Accrued expenses 6,623 8,536 Income tax payable 324 531 Lease liability - current portion 39 266 Total current liabilities 14,325 14,076 Stockholders' equity: Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively — — Common stock, $0.001 par value; 240,000,000 shares authorized; 41,439,529 and 38,329,894 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 41 38 Additional paid-in capital 505,207 502,501 Accumulated other comprehensive loss (82) (120) Accumulated deficit (499,449) (467,371) Total stockholders' equity 5,717 35,048 Total liabilities and stockholders' equity $ 20,042$ 49,124 Leap Therapeutics, Inc. Condensed Consolidated Statements of Cash Flows (in thousands) (Unaudited) (Unaudited) Three Months Ended June 30 Six Months Ended June 30 20252024 20252024 Cash used in operating activities $ (14,486)$ (13,671) $ (28,966)$ (29,187) Cash provided by (used in) financing activities (119)37,117 (180)37,146 Effect of exchange rate changes on cash and cash equivalents 22112 27(123) Net increase (decrease) in cash and cash equivalents (14,583)23,558 (29,119)7,836 Cash and cash equivalents at beginning of period 32,71354,921 47,24970,643 Cash and cash equivalents at end of period $ 18,130$ 78,479 $ 18,130$ 78,479 View original content to download multimedia: SOURCE Leap Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Deere narrows full-year profit outlook; shares fall
-- Deere & Company reported better-than-expected third-quarter results on Thursday, but shares fell 5% as the farm equipment manufacturer narrowed its full-year profit guidance amid ongoing market challenges. The agricultural machinery giant posted adjusted earnings of $4.75 per share for the quarter ended July 27, 2025, exceeding analyst expectations of $4.58. Revenue came in at $10.6 billion, above the consensus estimate of $10.35 billion, though still down 9% compared to the same period last year. Deere narrowed its full-year net income guidance to between $4.75 billion and $5.25 billion, compared to its previous forecast of $4.75 billion to $5.50 billion, reflecting continued caution about market conditions. The company cited customer hesitancy amid ongoing uncertainty in the agricultural sector. "By proactively managing inventory, we've matched production to retail demand, enabling our company and dealers to respond swiftly to market shifts and customer needs," said John May, chairman and CEO of John Deere. "By continuing to address the high levels of used equipment in the industry, we're building a healthier market for everyone." The company's Production & Precision Agriculture segment saw a 16% decline in sales and a 50% drop in operating profit compared to the same quarter last year. Small Agriculture & Turf sales decreased slightly by 1%, while Construction & Forestry sales fell 5%. Deere's financial services division was a bright spot, with net income increasing 34% to $205 million, driven by a lower provision for credit losses. Despite current challenges, the company remains focused on its technology offerings. "The increasing utilization and proven in-field effectiveness of advanced technologies—such as See & Spray and Harvest Settings Automation—are empowering customers to improve their productivity and better navigate industry challenges," May added. For fiscal 2025, Deere expects U.S. and Canada large agriculture equipment sales to decline approximately 30%, while small agriculture and turf equipment sales are projected to decrease around 10%. Related articles Deere narrows full-year profit outlook; shares fall Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse After soaring 149%, this stock is back in our AI's favor - & already +25% in July Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
